CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma

FDA
  • August 27, 2020

A CAR T-cell therapy called brexucabtagene autoleucel (Tecartus) has been approved by the Food and Drug Administration (FDA) for some patients with mantle cell lymphoma. This is the third CAR-T cell therapy approved by FDA for patients with cancer.

Read more >

© 2021 FLASCO | Premium Website Design by The HDG

FLASCO